Predictive and Prognostic Role of Metabolic Response in Patients With Stage III NSCLC Treated With Neoadjuvant Chemotherapy.

Angelo Castello,Luca Toschi,Sabrina Rossi,Giovanna Finocchiaro,Fabio Grizzi,Emanuela Mazziotti,Dorina Qehajaj,Daoud Rahal,Egesta Lopci

Clinical Lung Cancer（2020）

引用 6|浏览67

暂无评分

摘要

Several metabolic parameters may differentiate responders from non-responders following neoadjuvant chemotherapy in stage III NSCLC. As compared with RECIST 1.1, EORTC seems to be more appropriate for evaluation therapeutic response. Finally, post-TLG_N has significant prognostic information.

查看译文

关键词

18F-FDG PET/CT,Metabolic response,Neoadjuvant treatment,Non–small-cell lung cancer,Prognostic value

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要